View in EDS HTML Full Text PDF Full Text

Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.

Saved in:
Bibliographic Details
Title: Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.
Authors: Shretta, R, Brugha, R, Robb, A, Snow, R W
Source: Lancet. 5/13/2000, Vol. 355 Issue 9216, p1718-1720. 3p.
Subjects: Drug therapy for malaria, Health policy, Antimalarials, Drugs, Public health & economics, Cost effectiveness, Charities, Industries & economics, Combination drug therapy, Comparative studies, Developing countries, Research methodology, Medical cooperation, Quinone, Research, Evaluation research, Atovaquone, Economics
Geographic Terms: Kenya
Abstract: Considers the implications of corporate drug donations for national drug policies and long-term spending choices within the context of the Malarone Donation Programme in Kenya. Situation in Kenya with a problem of sulphadoxine-pyrimethamine failures in malaria treatment and need for alternative drugs; Sustainability and affordability of the antmalarial treatment; Prerequisites for equitable access to the drug.
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 3102366
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Shretta%2C+R%22">Shretta, R</searchLink><br /><searchLink fieldCode="AR" term="%22Brugha%2C+R%22">Brugha, R</searchLink><br /><searchLink fieldCode="AR" term="%22Robb%2C+A%22">Robb, A</searchLink><br /><searchLink fieldCode="AR" term="%22Snow%2C+R+W%22">Snow, R W</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 5/13/2000, Vol. 355 Issue 9216, p1718-1720. 3p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+therapy+for+malaria%22">Drug therapy for malaria</searchLink><br /><searchLink fieldCode="DE" term="%22Health+policy%22">Health policy</searchLink><br /><searchLink fieldCode="DE" term="%22Antimalarials%22">Antimalarials</searchLink><br /><searchLink fieldCode="DE" term="%22Drugs%22">Drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Public+health+%26+economics%22">Public health & economics</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+effectiveness%22">Cost effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Charities%22">Charities</searchLink><br /><searchLink fieldCode="DE" term="%22Industries+%26+economics%22">Industries & economics</searchLink><br /><searchLink fieldCode="DE" term="%22Combination+drug+therapy%22">Combination drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Developing+countries%22">Developing countries</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Quinone%22">Quinone</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Atovaquone%22">Atovaquone</searchLink><br /><searchLink fieldCode="DE" term="%22Economics%22">Economics</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Kenya%22">Kenya</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Considers the implications of corporate drug donations for national drug policies and long-term spending choices within the context of the Malarone Donation Programme in Kenya. Situation in Kenya with a problem of sulphadoxine-pyrimethamine failures in malaria treatment and need for alternative drugs; Sustainability and affordability of the antmalarial treatment; Prerequisites for equitable access to the drug.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=3102366
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(00)02251-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 3
        StartPage: 1718
    Subjects:
      – SubjectFull: Drug therapy for malaria
        Type: general
      – SubjectFull: Health policy
        Type: general
      – SubjectFull: Antimalarials
        Type: general
      – SubjectFull: Drugs
        Type: general
      – SubjectFull: Public health & economics
        Type: general
      – SubjectFull: Cost effectiveness
        Type: general
      – SubjectFull: Charities
        Type: general
      – SubjectFull: Industries & economics
        Type: general
      – SubjectFull: Combination drug therapy
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Developing countries
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Quinone
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Atovaquone
        Type: general
      – SubjectFull: Economics
        Type: general
      – SubjectFull: Kenya
        Type: general
    Titles:
      – TitleFull: Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shretta, R
      – PersonEntity:
          Name:
            NameFull: Brugha, R
      – PersonEntity:
          Name:
            NameFull: Robb, A
      – PersonEntity:
          Name:
            NameFull: Snow, R W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 05
              Text: 5/13/2000
              Type: published
              Y: 2000
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 355
            – Type: issue
              Value: 9216
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1